基本信息
views: 33
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research Profile
Obesity is a major risk factor of type 2 diabetes (T2DM), insulin resistance and cardiovascular diseases (CVDs). In obesity, chronic metabolic stresses trigger adipose tissue inflammation and promote macrophage infiltration, resulting in aberrant secretion of bioactive peptides (known as adipokines). Our primary research interest is to investigate the role of adipokines in the pathogenesis of obesity-related insulin resistance, systemic inflammation, T2DM and vascular dysfunctions in animal models and human subjects. Our long-term goal is to develop adipokine-based diagnostic and therapeutic strategies for obesity-related cardio-metabolic complications. Our ongoing research projects include:
Identification and functional characterization of adipokine netowork: Using an integrated proteomics-based approach, we have identified multiple posttranslationally modified isoforms of adiponectin, and have demonstrated that hydroxylation and subsequent glycosylation of several lysine residues at the collagenous domain are obligatory for insulin-sensitizing effects of adiponectin by promoting the formation of high molecular weight oligomeric complexes (Wang Y, JBC, 2002, 2005, 2006; Biohcem. J, 2008; Xu A, JCI, 2003). We have also identified the circulating form of adipocyte fatty acid-binding protein (A-FABP) and lipocalin-2 as pro-inflammatory adipokines mediating toxic lipids-induced insulin resistance and vascular dysfunction (Xu A, Clin Chem: 2006; Circulation: 2007; Hui X, JBC:2010). More recently, we have demonstrated that fibroblast growth factor (FGF21), an anti-diabetic hormone traditionally thought to be produced from hepatocytes, is also secreted from adipose tissues (Zhang X, Diabetes, 2008 and Lin Z, Cell Metabolism, 2013). Furthermore, we found that adipose-derived FGF21 exerts its anti-diabetic activities by inducing adiponectin production (Fig 1). Currently, we are investigating the mechanisms by which FGF21 controls adiponectin production under physiological and pathological conditions.
2. Signaling mechanisms underlying the insulin-sensitizing and vascular protective effects of adiponectin: Adiponectin is one of the few adipokines with insulin-sensitizing and cardiovascular protective properties, but its mechanisms of actions remain poorly characterized. In 2007, We identified APPL1, an intracellular adaptor protein, as a key signaling molecule that bind to adiponectin receptors mediating adiponectin-induced activation of AMP-activated protein kinase (AMPK), thereby inducing eNOS activation and NO production in endothelial cells (Cheng KK, Diabetes, 2007). Our subsequent studies demonstrated that APPL1 is also a key component of insulin-evoked signaling cascade, by promoting membrane targeting and translocation of the protein kinase Akt (Cheng KK, Cell Metab. 2009; BJ, 2013). Furthermore, using APPL1 transgenic and knockout mice, we have found that APPL1 plays a central role in controlling vascular homeostasis as well as insulin secretion (Cheng KK, PNAS, 2012; Wang Y, Diabetes, 2011).
We have also uncovered an important role of adiponectin in preventing diabetes-induced vascular injury, by promoting the functions of endothelial progenitor cells (EPCs) via an AMPK-dependent mechanism (Chang J, Diabetes, 2010). In light of the key role of AMPK in mediating the endothelium-protective effects of adiponectin, we have generated transgenic mice with endothelium-selective constitutive AMPK activation, and found that endothelium-selective activation of AMPK is sufficient to prevent diabetes-associated impairment of vascular repair via induction of heme oxygenase-1 (HO1) pathway, which in turn augments EPCs-mediated endothelial regeneration (Li Y, Circulation, 2012) (Fig 2). We are currently investigating the roles of FGF21/adiponectin axis in protecting obesity-induced vascular inflammation and atherosclerosis in both rodents and large animals.
Obesity is a major risk factor of type 2 diabetes (T2DM), insulin resistance and cardiovascular diseases (CVDs). In obesity, chronic metabolic stresses trigger adipose tissue inflammation and promote macrophage infiltration, resulting in aberrant secretion of bioactive peptides (known as adipokines). Our primary research interest is to investigate the role of adipokines in the pathogenesis of obesity-related insulin resistance, systemic inflammation, T2DM and vascular dysfunctions in animal models and human subjects. Our long-term goal is to develop adipokine-based diagnostic and therapeutic strategies for obesity-related cardio-metabolic complications. Our ongoing research projects include:
Identification and functional characterization of adipokine netowork: Using an integrated proteomics-based approach, we have identified multiple posttranslationally modified isoforms of adiponectin, and have demonstrated that hydroxylation and subsequent glycosylation of several lysine residues at the collagenous domain are obligatory for insulin-sensitizing effects of adiponectin by promoting the formation of high molecular weight oligomeric complexes (Wang Y, JBC, 2002, 2005, 2006; Biohcem. J, 2008; Xu A, JCI, 2003). We have also identified the circulating form of adipocyte fatty acid-binding protein (A-FABP) and lipocalin-2 as pro-inflammatory adipokines mediating toxic lipids-induced insulin resistance and vascular dysfunction (Xu A, Clin Chem: 2006; Circulation: 2007; Hui X, JBC:2010). More recently, we have demonstrated that fibroblast growth factor (FGF21), an anti-diabetic hormone traditionally thought to be produced from hepatocytes, is also secreted from adipose tissues (Zhang X, Diabetes, 2008 and Lin Z, Cell Metabolism, 2013). Furthermore, we found that adipose-derived FGF21 exerts its anti-diabetic activities by inducing adiponectin production (Fig 1). Currently, we are investigating the mechanisms by which FGF21 controls adiponectin production under physiological and pathological conditions.
2. Signaling mechanisms underlying the insulin-sensitizing and vascular protective effects of adiponectin: Adiponectin is one of the few adipokines with insulin-sensitizing and cardiovascular protective properties, but its mechanisms of actions remain poorly characterized. In 2007, We identified APPL1, an intracellular adaptor protein, as a key signaling molecule that bind to adiponectin receptors mediating adiponectin-induced activation of AMP-activated protein kinase (AMPK), thereby inducing eNOS activation and NO production in endothelial cells (Cheng KK, Diabetes, 2007). Our subsequent studies demonstrated that APPL1 is also a key component of insulin-evoked signaling cascade, by promoting membrane targeting and translocation of the protein kinase Akt (Cheng KK, Cell Metab. 2009; BJ, 2013). Furthermore, using APPL1 transgenic and knockout mice, we have found that APPL1 plays a central role in controlling vascular homeostasis as well as insulin secretion (Cheng KK, PNAS, 2012; Wang Y, Diabetes, 2011).
We have also uncovered an important role of adiponectin in preventing diabetes-induced vascular injury, by promoting the functions of endothelial progenitor cells (EPCs) via an AMPK-dependent mechanism (Chang J, Diabetes, 2010). In light of the key role of AMPK in mediating the endothelium-protective effects of adiponectin, we have generated transgenic mice with endothelium-selective constitutive AMPK activation, and found that endothelium-selective activation of AMPK is sufficient to prevent diabetes-associated impairment of vascular repair via induction of heme oxygenase-1 (HO1) pathway, which in turn augments EPCs-mediated endothelial regeneration (Li Y, Circulation, 2012) (Fig 2). We are currently investigating the roles of FGF21/adiponectin axis in protecting obesity-induced vascular inflammation and atherosclerosis in both rodents and large animals.
Research Interests
Papers共 819 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
International Journal of Computer Mathematicspp.1-11, (2024)
ELIFE (2024)
Jiaqi Zhou,Weiyi Xia,Jiajia Chen, Kaijia Han, Yuxin Jiang, Anyuan Zhang,Dongcheng Zhou,Danyong Liu,Jiefu Lin,Yin Cai,Guanghua Chen,Liangqing Zhang,
Burns & trauma (2024): tkad055-tkad055
Lin Liu,Juanying Zhen,Shuyun Liu,Lijie Ren,Guoru Zhao, Jianguo Liang,Aimin Xu,Chao Li,Jun Wu,Bernard Man Yung Cheung
BMC Public Healthno. 1 (2024): 1-8
Life Sciences (2024): 122594-122594
Boya Liao,Shilun Yang,Leiluo Geng,Jiuyu Zong,Zixuan Zhang, Mengxue Jiang,Xue Jiang, Simeng Li,Aimin Xu,Junlei Chang,Ruby Lai Chong Hoo
BRITISH JOURNAL OF PHARMACOLOGYno. 8 (2024): 1238-1255
AIMS MATHEMATICSno. 1 (2024): 2051-2062
EMBO molecular medicineno. 3 (2024): 432-444
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn